Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: SIAH1 ubiquitination-modified HMGCR inhibits lung cancer progression and promotes drug sensitivity through cholesterol synthesis

Fig. 2

Cholesterol biosynthesis induced by HMGCR inhibits cisplatin sensitivity in lung adenocarcinoma cell lines

(A) The relative mRNA level of HMGCR in normal cells (BEAS-2B) and lung cancer cell lines (H1373, H1975, H441, and A549). (B) The protein level of HMGCR in normal cells (BEAS-2B) and lung cancer cell lines (H1373, H1975, H441, and A549). (C) The protein level of HMGCR in A549 and A549/DDP cells. (D) ELISA test kit was to detect cholesterol levels with or without cholesterol in the A549/DDP cell lines with knockout HMGCR. (E) The protein level of HMGCR with or without cholesterol in the A549/DDP cell lines with knockout HMGCR. (F) The IC50 of cisplatin with or without cholesterol in the A549/DDP cell lines with knockout HMGCR. The experiments were repeated three times. The experiments were repeated three times. For comparisons, a Student’s t-test was performed. *P < 0.05, and **P < 0.01

Back to article page